2024 UK Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Tests: Supplier Shares and Strategies, Volume and Sales Segment Forecasts by Test, Emerging Technologies, Latest Instrumentation
LeadingMarketResearch.com's new report is a is a new strategic analysis of major business opportunities emerging in the UK clinical chemistry and immunodiagnostic markets during the next five years. ; The report explores future trends in the UK market; provides estimates of the specimen, test and sales volumes, as well as major suppliers'; sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities emerging during the next five years.The report provides five-year volume and sales forecasts for over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays performed in hospitals, commercial laboratories, physician offices, and ambulatory care centers, including controls, calibrators and consumables.
I. Introduction
II. Market Overview
1. BUSINESS ENVIRONMENT
2. MARKET STRUCTURE
3. MARKET SIZE AND GROWTH
III. Major Product Development Opportunities
IV. Design Criteria for Decentralized Testing Products
V. Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized Testing Markets
VI. Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VII. Market and Technology Overview
A. Major Routine Chemistry Tests
1. ALBUMIN
2. ALKALINE PHOSPHATASE
3. ALT/SGPT
4. AMMONIA
Table of Contents (continued)
5. AMYLASE
6. AST/SGOT
7. BILIRUBIN, TOTAL
8. BLOOD GASES
9. BLOOD UREA NITROGEN (BUN)
10. CALCIUM
11. CARDIO CRP
12. CHOLESTEROL
13. CHOLINESTERASE
14. CRP
15. CREATININE
16. ELECTROLYTES
a. Carbon Dioxide/Bicarbonate
b. Chloride
c. Potassium
d. Sodium
17. FERRITIN
18. FRUCTOSAMINE
19. GAMMA-GLUTAMYL TRANSPEPTIDASE (GGT)
20. GLUCOSE
21. HIGH DENSITY LIPOPROTEIN (HDL)
22. HOMOCYSTEINE
23. IRON
24. LACTATE DEHYDROGENASE (LDH)
25. MAGNESIUM
26. PHOSPHORUS
27. PROTEIN
28. TRIGLYCERIDES
29. URIC ACID
30. TROPONIN
B. Therapeutic Drug Monitoring (TDM)
1. OVERVIEW
2. CARBAMAZEPINE
3. CYCLOSPORIN
4. DIGOXIN
5. EVEROLIMUS
6. GENTAMICIN
7. LAMOTRIGINE/LAMICTAL
8. LEVETIRACETAM
9. LIDOCAINE
10. LITHIUM
11. NAPA/PROCAINAMIDE
12. PHENYTOIN
13. QUINIDINE
II. Market Overview
1. BUSINESS ENVIRONMENT
2. MARKET STRUCTURE
3. MARKET SIZE AND GROWTH
III. Major Product Development Opportunities
IV. Design Criteria for Decentralized Testing Products
V. Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized Testing Markets
VI. Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VII. Market and Technology Overview
A. Major Routine Chemistry Tests
1. ALBUMIN
2. ALKALINE PHOSPHATASE
3. ALT/SGPT
4. AMMONIA
Table of Contents (continued)
5. AMYLASE
6. AST/SGOT
7. BILIRUBIN, TOTAL
8. BLOOD GASES
9. BLOOD UREA NITROGEN (BUN)
10. CALCIUM
11. CARDIO CRP
12. CHOLESTEROL
13. CHOLINESTERASE
14. CRP
15. CREATININE
16. ELECTROLYTES
a. Carbon Dioxide/Bicarbonate
b. Chloride
c. Potassium
d. Sodium
17. FERRITIN
18. FRUCTOSAMINE
19. GAMMA-GLUTAMYL TRANSPEPTIDASE (GGT)
20. GLUCOSE
21. HIGH DENSITY LIPOPROTEIN (HDL)
22. HOMOCYSTEINE
23. IRON
24. LACTATE DEHYDROGENASE (LDH)
25. MAGNESIUM
26. PHOSPHORUS
27. PROTEIN
28. TRIGLYCERIDES
29. URIC ACID
30. TROPONIN
B. Therapeutic Drug Monitoring (TDM)
1. OVERVIEW
2. CARBAMAZEPINE
3. CYCLOSPORIN
4. DIGOXIN
5. EVEROLIMUS
6. GENTAMICIN
7. LAMOTRIGINE/LAMICTAL
8. LEVETIRACETAM
9. LIDOCAINE
10. LITHIUM
11. NAPA/PROCAINAMIDE
12. PHENYTOIN
13. QUINIDINE
